Zusammenfassung
Seit Beginn der 80er Jahre ist die transarterielle Chemoembolisation (TACE) von Lebermetastasen Gegenstand zahlreicher Studien, ohne dass sich bisher ein einheitliches Therapiekonzept durchgesetzt hat.
Die vorgestellte Studie untersuchte bei 21 Patienten mit inoperablen Lebermetastasen kolorektaler Karzinome retrospektiv die Überlebenszeiten, Ansprechraten und Nebenwirkungen nach TACE, und die Ergebnisse werden den Daten der bisherigen Literatur gegenübergestellt. Insgesamt wurden 68 TACE durchgeführt. Eine Suspension aus abbaubaren Stärkepartikel (degradable starch microspheres, DSM; Spherex®) und Mitomycin C wurde über einen transfemoralen Zugang selektiv in die Leberarterien appliziert. DSM bewirkt eine temporäre arterielle Okklusion. Die Therapiekontrolle erfolgte mit kontrastmittelunterstützter Spiralcomputertomographie (CT).
Die mediane Überlebenszeit betrug 13,8 Monate. Ein Ansprechen (nach WHO-Kriterien) wurde lediglich bei 3 Patienten beobachtet, das progressfreie Intervall lag im Median bei 5,8 Monaten. Als Nebenwirkung traten ein Postembolisationssyndrom (abdominelle Schmerzen, Fieber, Übelkeit) sowie eine Erhöhung der Transaminasen bei 27–43% der Interventionen auf. Nach 4 TACE kam es zur Entstehung eines Magenulkus, nach 2 TACE zu einer Cholezystitis.
Wie in den meisten vorangegangenen Arbeiten, ungeachtet der eingesetzten Substanzen, ist auch in dieser Studie der therapeutische Effekt der TACE von Lebermetastasen kolorektaler Karzinome eher als mäßig einzustufen. Ein Überlebensvorteil gegenüber dem Spontanverlauf konnte bisher in der Literatur nicht eindeutig belegt werden, die Ansprechraten sind meistens sehr begrenzt. Komplikationen sind bei der TACE insgesamt selten, in ihrer Schwere aber nicht zu unterschätzen. Das Postembolisationssyndrom scheint beim Gebrauch abbaubarer Stärkepartikel im Vergleich zu Embolisaten mit lang anhaltender oder permanenter Okklusion seltener aufzutreten. Daher könnten unter palliativen Gesichtspunkten abbaubare Stärkepartikel von Vorteil sein. Sollten in Zukunft weitere Studien zur TACE von Lebermetastasen stattfinden, muss unter palliativen Gesichtspunkten mehr Augenmerk auf die Lebensqualität des Patienten gerichtet werden.
Abstract
Since two decades transarterial chemoembolization (TACE) of liver metastases has been investigated in numerous studies. However, no standardized therapeutic procedure exists so far.
The present study retrospectively investigated survival, response and side effects after TACE of liver metastases in 21 patients with colorectal cancer and results are compared with previous literature. A total of 68 TACE procedures were performed. A suspension of degradable starch microspheres (DSM, Spherex®) and Mitomycin C was applied selectively into hepatic arteries via a transfemoral approach. DSM effect a temporary arterial occlusion. Follow-up studies were performed by contrast enhanced spiral computed tomography (CT).
The median survival was 13.8 months. Therapeutic response (according to WHO) was observed only in three patients. The progression free interval was 5.8 months. Patients developed a postembolization-syndrome (abdominal pain, fever, nausea) and increased transaminases in 27–43% of all interventions. A gastric ulcer occurred after four, cholecystitis after two TACE.
As already shown in most previous studies, regardless of the used agents, also this investigation underlines the moderate therapeutic effect of TACE on colorectal liver metastases. So far, no significant survival benefit has been shown in the literature and the response rates are rather limited. In general, complications of TACE seem to be rare, but should not to be underestimated. Compared to TACE with long or permanent arterial occlusion, postembolization syndrome seems to be less pronounced using DSM. As TACE is rather a palliative therapeutic approach, DSM therefore might be more suited. Further studies on TACE of liver metastases should focus on to the patients’ quality of life.
Literatur
Ackerman NB, Lien WM, Kondi ES, Silverman NA (1969) The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to „small“ and „large“ tumors. Surgery 66:1067
Ackerman NB (1972) Experimental studies on the circulatory dynamics of intrahepatic tumor blood supply. Cancer 29:435–439
Amin Z, Bown SG, Lees WR (1993) Local treatment of colorectal liver metastases: a comparison of interstitial laser photocoagulation (ILP) and percutaneous alcohol injection (PAI). Clin Radiol 48:166–171
Aronsen KF, Hellekant C, Holmberg J, Rothmann U, Teder H (1979) Controlled blocking of hepatic artery flow with enzymatic degradable microspheres combined with oncolytic drugs. Eur Surg Resp 11:99–106
Bengmark S, Jeppson B, Lunderquist A, Tranberg KG, Persson B (1988) Tumor calcification following repeated hepatic dearteralization in patients: a preliminary communication. Br J Surg 75:525–526
Berger DH, Carrasco CH, Hohn DC, Curley SA (1995) Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 60 116–121
Bläcker H, Hofmann WJ, Theurer D, Otto HF (2001) Pathologische Befunde bei Lebermetastasen. Radiologe 41:1–7
Bleiberg H, Pector C, Frühling J, Parmentier N, Gerard B, Gordon BH, Ings RMJ, Solere P, Lucas C (1992) Hepatic intra-arterial fotemustine combined with degradable starch microspheres: pharmacokinetics in a phase I-II trial. Reg Cancer Treat 4:237–243
Borner M, Castiglione M, Triller J, Soucek M, Blumgart L, Brunner K (1992) Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Ann Oncol 3:113–115
Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–977
Civalleri D, Pector JC, Håkansson L, Arnaud JP, Duez N, Buyse M (1994) Treatment of patients with irresectable metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres. Br J Surg 81:1338–1341
Civalleri D, Scopinaro G, Balletto N, Claudiani F, DeCian F, Camerini G, DePaoli M, Bonalumi U (1989) Changes in vascularity of liver tumours after hepatic arterial embolization with degradable starch microspheres. Br J Surg 76:699–703
Czejka M, Jäger W, Schüller J, Schernthaner G (1991) Pharmakokinetik und lokale Verfügbarkeit von Mitomycin. Einfluß von Vasokonstriktion und Chemoembolisation. Arzneimittelforschung 41:260–263
De Dycker RP, Timmermann J (1991) Combined intraarterial hepatic infusion of degradable starch microspheres and cytostatics in the treatment of breast cancer liver metastases. Reg Cancer Treat 3:302–304
De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947
Eibl-Eibesfeld B, Aichner I, Izbicki J, Kummermehr J, Waldner H, Wilker D (1989) Interaktion von Mitomycin C und Tumorischämie. Langenbecks Arch Chir [suppl]:1–4
Ensminger WD, Gyves JW, Stetson P, Walker-Andrews S (1985) Phase I study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Res 45:4464–4467
Fiorentini G, Campanini A, Dazzi C, Davitti B, Graziani G, Priori T, Ricci Bitti R, Angelini L (1994) Chemoembolization in liver malignant involvement. Minerva Chir 49:281–285
Fujimoto S, Koike S, Takahashi M, Mutou T, Kure M, Kobayashi K, Okkubo H (1993) Intra-arterial infusion chemotherapy with degradable starch microspheres and mitomycin C for unresectable hepatic metastasis from gastrointestinal cancer. Reg Cancer Treat 1:7–11
Gennari L, Doci R, Veronesi U (1982) Proposal for a clinical classification of liver metastases. Tumori 68:443–449
Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147
Gross-Fengels W, Friedmann G, Kuhn M, Huber R, Dommasck J, Neufang KFR (1991) Techniken, Ergebnisse und Risiken der Chemoembolisation von malignen Lebertumoren. Akt Radiol 1:97–104
Haage P, Tacke J (2001) MR-gesteuerte perkutane Kryotherapie von Lebermetastasen. Radiologe 41:77–83
Håkansson L, Håkansson A, Morales O, Thorelius L, Warfving T (1997) Spherex (degradable starch microspheres) chemo-occlusion-enhancement of tumor drug concentration and therapeutic efficacy. an overview. Semin Oncol 24:100–109
Helmberger T, Holzknecht N, Schopf U, Kulinna C, Rau H, Stabler A, Reiser M(2001) Radiofrequenzablation von Lebermetastasen. Technik und erste Ergebnisse. Radiologe 41:69–76
Herfarth C, Hohenberger P (1989) Chirurgie der Metastasenleber. Langenbecks Arch Chir [suppl II]:263–268
Herfarth KK, Debus J, Lohr F, Bahner ML, Wannenmacher M (2001) Stereotaktische Bestrahlung von Lebermetastasen. Radiologe 41:64–68
Hobday TJ, Goldberg RM (2002) Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer 2:161–169
Hunt TM, Flowerdew ADS, Birch SJ, Williams JD, Mullee MA, Taylor I (1990) Prospective randomized controlled trial of hepatic arterial embolization of infusion chemotherapy with 5-fluoruracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 77:779–782
Isenberg J, Fischbach R, Krüger I, Keller HW (1996) Treatment of liver metastases from colorectal cancer. Anticancer Res 16:1291–1296
Kameyama M, Imaoka S, Fukuda I, Nakamori S, Sasaki Y, Fujita I, Hasegawa Y, Iwanaga T (1992) Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastasis of colorectal cancer. Surgery 114:97–101
Kemen N, Niedzwiecki D, Shurgot B, Odermann P (1989) Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 63:742–747
Kettenbach J, Pokrajac B, Schamp S, Fellner C, Schmid R, Gustorff B, Berger J, Grgurin M, Peer K, Wolff U, Seitz W, Potter R, Lammer J (2001) MR-gestützte Brachytherapie nichtresektabler Lebermetastasen. Vorläufige technische und klinische Erfahrungen. Radiologe 41:56–63
Kobayashi H, Inoue H, Shimada J, Yano T, Maeda T, Oyama T, Shinohara S (1987) Intra-arterial injection of adriamycin/mitomycin C lipiodol suspension in liver metastases. Acta Radiol 28:275–280
Köhne-Wömpner HJ, Schmoll HJ, Harstrick A, Rustum YM (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol 19 [suppl 3]:105–125
Lang EK, Brown CL (1993) Colorectal metastases to the liver: selective chemoembolization. Radiology 189:417–422
Lehnert T, Golling M (2001) Indikation und Ergebnisse der Lebermetastasenresektion. Radiologe 41:40–48
Leichmann CG, Jacobson JR, Modiano M, Daniels JR, Zalupski MM, Dorishow JH, Fletcher WS, Macdonald JS (1999) Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucoverin for patients with metastatic colorectal carcinoma: a Southwest Oncology Group Pilot Trial. Cancer 86:775–781
Lin G, Lunderquist A, Hägerstrand I, Boijsen E (1984) Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 96:517–526
Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 18:1734–1739
Lorenz M, Hermann G, Kirkowa-Reinmann M, Herrhausen T, Henne T, Hottenrott C (1989) Temporary chemoembolization of colorectal liver metastases with degradable starch microspheres. Eur J Surg Oncol 15:453–462
Martinelli DJ, Wadler S, Bakal CW, Cynamon J, Rozenblit A, Haynes H, Kaleya R, Wiernik PH (1994) Utility of embolization or chemoembolization as second-line-treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 74:1706–1712
Meakem TJ, Unger EC, Pond GD, Modiano MR, Alberts DR (1992) CT findings after hepatic chemoembolization. J Comput Assist Tomogr 16:916–920
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Patt Y, Chuang V, Wallace S, Hersh E, Freireich E, Mavligit G (1981) The palliative role of hepatic arterial infusion and arterial occlusion in colorectal carcinoma metastatic to the liver. Lancet 1:349–350
Pentecost MJ (1993) Transcatheter treatment of liver metastases. Am J Roentgenol 160:1171–1175
Persson B, Jeppson B, Ekberg H (1990) Repeated dearteralization of hepatic tumors with an implantable occluder. Cancer 66:1139–1146
Pickren JW, Tsukada Y, Lane WW (1982) Liver metastases: analysis of autopsy data. In: Gilbert HA, Weiss L (eds) Liver metastases. Hall Medical Publishers, Boston, pp 2–18
Richter EI, Schultheis KH, Gebhardt C, Wurzer W (1992) Indikation zur Chemoembolisation maligner Tumoren. Radiologe 32:56–59
Sanz-Altamira MP, Spence LD, Hubermann MS, Posner MR, Steele G, Perry LJ, Stuart KE (1997) Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma. Dis Colon Rectum 40:770–775
Schultheis KH, Gebhardt C, Schwemmle K, Richter EI, Schmacher F (1990) Chemoembolisation kolorektaler Metastasen. Zent Bl Chir 115:933–947
Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405–1410
Starkhammer H, Håkansson L, Morales O, Svedberg J (1987) Intra-arterial mitomycin C treatment of unresectable liver tumours. Acta Oncol 26:295–300
Strohmeyer T, Haugeberg G, Lierse W (1986) Vaskularisation von Lebermetastasen: eine korrosionsanatomische Studie. Acta Anat 126:172–176
Taguchi T, Ogawa N, Bunke B, Nilsson B, DSM Study Group (1992) The use of degradable starch microspheres (spherex) with intra-arterial chemotherapy for the treatment of primary and secondary liver tumors—results of a phase III clinical trial. Reg Cancer 4:161–165
Taguchi T (1994) Chemo-occlusion in the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet 26:176–191
Taniguchi H, Takahashi T, Yamaguchi T, Kiyoshi S (1989) Intraarterial infusion chemotherapy for metastatic liver tumors using multiple anti-cancer agents suspended in a lipid contrast medium. Cancer 64:2001–2006
Tellez C, Benson AB, Lyster MT, Talamonti M, Shaw J, Braun MA, Nemcek AA, Vogelzang RL (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82:1250–1259
Vogl T, Mack M, Straub R, Zangos S, Woitaschek D, Eichler K, Engelmann K (2001) Thermische Ablation von Lebermetastasen. Aktueller Stand und Perspektiven. Radiologe 41:49–55
Vogl TJ, Zangos S, Balzer JO, Thalhammer A, Mack MG (2002) Transarterielle Chemoembolisation von Lebermetastasen: Indikationsstellung, Technik, Ergebnisse. Fortschr Röntgenstr 174:675–683
Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ (2002) A new chemoembolization protocol in refractory liver metastasis of colorectal cancer—feasability study. Onkologe 25:158–164
Wagner JS, Adson MA, Heerden JA (1984) The natural history of hepatic metastases from colorectal cancer. Ann Surg 199:502–507
Wollner IS, Walker-Andrews SC, Smith JE, Ensminger WD (1986) Phase II study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Drug Deliv 4:279–284
Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 7:285–288
Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, Sato N, Nakashima K, Urata J, Yoshizumi K, Ito K, Sumi S (1990) Prognostic factors in liver metastases after transcatheter arterial embolization or arterial infusion. Acta Radiol 31:269–274
Interessenkonflikt:
Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wasser, K., Giebel, F., Fischbach, R. et al. Transarterielle Chemoembolisation von Lebermetastasen kolorektaler Karzinome mit abbaubaren Stärkepartikeln (Spherex®). Radiologe 45, 633–643 (2005). https://doi.org/10.1007/s00117-004-1061-5
Issue Date:
DOI: https://doi.org/10.1007/s00117-004-1061-5